Preview

Nephrology (Saint-Petersburg)

Advanced search

THE INFLUENCE OF LONGTERM DIFFERENTIATERD HYPOLIPIDEMIC THERAPY ON LIPID AND PLEIOTROPIC EFFECTS AND FREQUENCY OF ATTAINMENT OF TERMINAL POINTS FOR NORMOTENSIVE CHRONIC GLOMERULONEPHRITIS PATIENTS

https://doi.org/10.24884/1561-6274-2006-10-3-43-47

Abstract

THE AIM of the investigation was to comparatively assess the frequency of attaining the desired levels of lipids in chronic glomerulonephritis patients with hyperlipidemia known to be one of metabolic potentially modifying factors of progress of chronic glomerulonephritis, against the background of treatment with statins, fibrates and nicotinic acid as well as the influence of such therapy on certain laboratory indices and frequency of attainment of the terminal points. PATIENTS AND METHODS. The investigation included 36 primary chronic glomerulonephritis patients with a noncompromised function of the kidneys. The patients were divided into three groups depending on the hyperlipidemia phenotype. The first group consisted of 12 patients treated with statins, the second group (10 patients) treated with nicotinic acid, and the third group (14 patients) treated with phenofibrate. The total duration of the investigation was 25 months. RESULTS. The frequency of attaining the desired levels of lipids in the blood during 25 months of treatment was as follows: for statins – 66.7%, for fibrates - 57.1%, for nicotinic acid – 50%. The anti-inflammatory effect of statins manifested itself as a decrease of C reactive protein and diurnal proteinuria. Nicotinic acid facilitates the formation of hyperuricemia. Phenofibrate has hypouricemic, anti-inflammatory and fibrinolytic properties. CONCLUSION. The treatment with statins and fibrates, in a greater extent than nicotinic acid, allowed frequency of the development of chronic renal failure and arterial hypertension to be decreased, and the non-fatal myocardial infarction to be prevented.

About the Author

I. V. Mukhin
Донецкий государственный медицинский университет им. М. Горького
Ukraine


References

1. Смирнов АВ. Дислипопротеидемии и проблемы нефропротекции. Нефрология 2002; (2): 8-14

2. Батюшин ММ. Нефрология: основы доказательной терапии.Феникс, Ростов на Дону, 2005; 348

3. Волков ВИ. Атеросклероз и атеротромбоз: патогенез, клинические проявления, лечение. Лікування та діагностика 2002; (2): 13-22

4. Гвозденко ТА, Антонюк МВ, Новгородцева ТП. К вопросу о липидных нарушениях у больных хроническим пиелонефритом. Нефрология 2006; 1: 50-55

5. Fried ZF, Orchard TJ, Kasiske BZ. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269

6. Колина ИБ, Ставровская ЕВ, Шилов ЕМ. Дислипидемия и хронические прогрессирующие заболевания почек. Тер арх 2004; (9): 75-78

7. Корякова НН. Патогенетические механизмы ренопротективного действия статинов при хроническом гломерулонефрите. Нефрология 2005; (3): 57-59

8. Пиріг ЛА. Патогенетичне лікування імуноопосередкованих гломерулопатій. Мистецтво лікування 2004; (2): 10-13

9. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceri-daemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42

10. Bruckert E, Baigts F. Comparison of the efficacy of the simvastatinas standard fibrate therapy in the treatment of primary hypercholestrolemia and combined hyperlipidemia. Clin Cardiol 1995; 18: 621-629

11. Latoszek L, Szostak WB. Comparative studies on the influence of different fibrates on serum lipoprotein in endogenous hyperlipoproteinemia. Eur J Clin Pharmaco l1991; 40: 33-34


Review

For citations:


Mukhin I.V. THE INFLUENCE OF LONGTERM DIFFERENTIATERD HYPOLIPIDEMIC THERAPY ON LIPID AND PLEIOTROPIC EFFECTS AND FREQUENCY OF ATTAINMENT OF TERMINAL POINTS FOR NORMOTENSIVE CHRONIC GLOMERULONEPHRITIS PATIENTS. Nephrology (Saint-Petersburg). 2006;10(3):43-47. (In Russ.) https://doi.org/10.24884/1561-6274-2006-10-3-43-47

Views: 893


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)